Tirzepatide vs Semaglutide
Tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy) are the two dominant FDA-approved GLP-1 medications for weight loss and type 2 diabetes. Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist ("twincretin") that consistently produces greater weight loss in clinical trials — approximately 22.5% of body weight versus semaglutide's 14.9% — while semaglutide offers a longer track record, proven cardiovascular benefit from the SELECT trial, and an oral formulation. Your best choice depends on your primary goal, budget, side-effect tolerance, and cardiovascular history.
Based on 12+ peer-reviewed studies including SURMOUNT-1, STEP-1, SURPASS-2, and SELECT trials. All data from published clinical research. Not medical advice — consult your provider.
Quick Answer
Tirzepatide and semaglutide are both weekly GLP-1 injections, but tirzepatide adds GIP receptor activity, delivering roughly 22.5% body weight loss (SURMOUNT-1) versus semaglutide's 14.9% (STEP-1). Tirzepatide also tends to cause less nausea at equivalent efficacy. Semaglutide has proven cardiovascular benefit (SELECT trial) and an oral option (Rybelsus). Consult your provider to determine which fits your goals, budget, and health history.
Which GLP-1 is right for you?
This tool is for educational reference only. Answer four questions and get a starting point for your conversation with a healthcare provider. It does not constitute medical advice.
Which GLP-1 is right for you?
Answer 4 questions — get a personalized starting point
Question 1 of 4
What is your primary goal?
At-a-Glance Comparison
| Metric | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist ("twincretin") — activates both incretin pathways simultaneously | GLP-1 receptor agonist only — single incretin pathway |
| FDA approvals | T2D: Mounjaro (May 2022) · Obesity: Zepbound (Nov 2023) | T2D: Ozempic (Dec 2017) · Obesity: Wegovy (Jun 2021) |
| Average weight loss (pivotal trial) | ~22.5% body weight at 72 weeks (SURMOUNT-1, highest dose) | ~14.9% body weight at 68 weeks (STEP-1, 2.4 mg) |
| Dosing schedule | Once weekly subcutaneous injection (2.5 → 5 → 10 → 15 mg) | Once weekly subcutaneous injection or daily oral tablet (Rybelsus for T2D) |
| A1C reduction (T2D) | ~2.0–2.3% average reduction (SURPASS program) | ~1.5–1.8% average reduction (SUSTAIN program) |
| Half-life | ~5 days | ~7 days |
| GI side effects (nausea) | ~31% nausea (vs 44% sema at comparable efficacy doses) | ~44% nausea in STEP-1 at max dose |
| Cardiovascular evidence | SURPASS-CVOT ongoing; positive secondary endpoints in SURPASS trials | 20% MACE reduction proven in SELECT trial (37,000+ patients) |
| Oral option available | No (oral formulation in Phase 3 development) | Yes — Rybelsus (3/7/14 mg daily) approved for T2D |
| Cost (branded, US list price) | ~$1,060–$1,200/month (Zepbound/Mounjaro) | ~$935–$1,430/month (Wegovy/Ozempic) |
| Compounded availability (2026) | Available from 503B facilities; FDA shortage list status evolving | FDA removed from shortage list (early 2024); compounded versions in legal gray area |
| Years on market | ~3 years (since 2022) | ~9 years (since 2017) |
| Weight loss durability (off-drug) | Expected similar to sema — trials ongoing | Two-thirds of weight loss regained within 1 year of stopping (STEP 1 extension) |
Clinical Trial Evidence: SURMOUNT-1 vs STEP-1
The two landmark trials that established efficacy benchmarks for each drug use similar designs — allowing a meaningful, though indirect, comparison. Neither has been directly compared in a randomized obesity trial, but the SURPASS-2 trial provides a direct head-to-head in T2D patients.
Tirzepatide · SURMOUNT-1
Jastreboff et al., NEJM 2022
- Participants
- 2,539 adults with obesity/overweight (no T2D)
- Duration
- 72 weeks
- Avg. weight loss (15 mg)
- ~22.5%
- ≥20% weight loss achieved
- ~57% of participants
- vs. placebo
- +17.8 pp over placebo
- PubMed
- PMID 35658024
Semaglutide · STEP-1
Wilding et al., NEJM 2021
- Participants
- 1,961 adults with obesity/overweight (no T2D)
- Duration
- 68 weeks
- Avg. weight loss (2.4 mg)
- ~14.9%
- ≥20% weight loss achieved
- ~32% of participants
- vs. placebo
- +12.4 pp over placebo
- PubMed
- PMID 33567185
Head-to-Head: SURPASS-2 Trial
The SURPASS-2 trial (PMID 34170647) directly compared tirzepatide vs semaglutide 1 mg in 1,879 patients with T2D for 40 weeks. Tirzepatide at all doses (5 mg, 10 mg, 15 mg) produced superior A1C reductions and weight loss compared to semaglutide 1 mg weekly. At the 15 mg dose, tirzepatide produced a mean weight loss of ~11.2 kg versus 5.3 kg for semaglutide 1 mg — though it is important to note that Wegovy uses a 2.4 mg weekly dose for obesity, not the 1 mg dose tested in SURPASS-2.
The SELECT Trial (Semaglutide Cardiovascular Outcomes)
The SELECT trial (PMID 37952131) enrolled 17,604 adults with overweight or obesity and established cardiovascular disease. Semaglutide 2.4 mg weekly reduced the risk of major adverse cardiovascular events (MACE — heart attack, stroke, or cardiovascular death) by 20% versus placebo over approximately 3.3 years. This trial is unique in the GLP-1 space: tirzepatide does not yet have equivalent cardiovascular outcomes data from a dedicated large outcomes trial.
Cost Comparison: Branded vs Compounded
Out-of-pocket costs for GLP-1 medications can be significant without insurance coverage. The table below reflects approximate 2026 US pricing; actual costs vary by dose, pharmacy, and coverage.
| Option | Tirzepatide | Semaglutide |
|---|---|---|
| Branded (list price/month) | ~$1,060–$1,200 (Zepbound/Mounjaro) | ~$935–$1,430 (Wegovy/Ozempic) |
| With manufacturer savings card | As low as $550/month (Zepbound savings program) | As low as $25/month for some commercially insured patients |
| Compounded (503B facility) | ~$200–$450/month (where legally available) | ~$150–$400/month (legal status varies by state) |
| Insurance coverage (obesity) | Variable — improving under Medicare Part D reforms | Variable — Wegovy covered by some plans; Ozempic often covered for T2D |
| Cost per 1% body weight lost* | ~$53/month per 1% loss (at max dose, avg) | ~$70/month per 1% loss (at max dose, avg) |
*Rough calculation based on average weight loss from pivotal trials at highest approved doses. Individual results vary significantly. Consult your provider and insurer about coverage options before making cost-based decisions.
Insurance notes: Medicare Part D plans are now required to cover anti-obesity medications approved after January 2026, which may improve access to both drugs. Many commercial insurers cover GLP-1s for type 2 diabetes (Mounjaro/Ozempic) more readily than for obesity. Prior authorization requirements vary. Telehealth providers (listed below) often help navigate prior authorization.
On compounded medications: The FDA has issued guidance on compounded tirzepatide and semaglutide. Legal availability depends on FDA shortage list status, which has changed over time. Always verify that any compounding pharmacy is a 503B-registered outsourcing facility. Discuss the legal status and quality considerations with your prescribing provider.
Side Effects Comparison
Both medications share a similar GI side effect profile due to their GLP-1 receptor activity. The differences are primarily in magnitude rather than type.
| Side Effect | Tirzepatide | Semaglutide |
|---|---|---|
| Nausea | ~31% (SURPASS-2 vs 44% sema at comparable doses) | ~44% (STEP-1 at 2.4 mg) |
| Vomiting | ~12% | ~24% |
| Diarrhea | ~23% | ~30% |
| Constipation | ~11% | ~24% |
| Decreased appetite | ~36% | ~29% (mechanism of weight loss) |
| Injection site reaction | ~3% | ~3% |
| Hypoglycemia (T2D, no insulin) | Very low (<1%) | Very low (<1%) |
| Pancreatitis (rare, serious) | Rare; listed as warning | Rare; listed as warning |
| Thyroid C-cell tumors (rodent data) | Black box warning (rodent tumors; human relevance unknown) | Black box warning (same class effect) |
| Contraindicated in | Personal/family history of MTC or MEN2 | Personal/family history of MTC or MEN2 |
GI side effects typically peak during dose escalation (the first 4–12 weeks) and diminish as the body adapts. A slower titration schedule — staying at each dose for 8 weeks rather than 4 — meaningfully reduces side effect burden for both drugs. Consult your provider if GI side effects are severe or persistent.
Who Should Choose Which
This is an evidence-based decision guide, not a prescription. The following reflects current clinical trial data. Always work with a qualified healthcare provider to determine what is appropriate for your specific health profile.
Consider Tirzepatide if…
- ✓Your primary goal is maximum weight loss — studies show approximately 22.5% body weight loss vs semaglutide's ~15%
- ✓You have plateaued on semaglutide — the dual mechanism may produce renewed response
- ✓You need aggressive A1C reduction for T2D — tirzepatide produces greater glycemic improvement
- ✓You experienced significant nausea on semaglutide — tirzepatide tends to cause fewer GI side effects at comparable efficacy doses
- ✓You have no established cardiovascular disease and cardiovascular outcomes data is less of a deciding factor
Consider Semaglutide if…
- ✓You have established cardiovascular disease or high MACE risk — only semaglutide has proven 20% MACE reduction (SELECT trial)
- ✓You prefer an oral medication — Rybelsus (oral semaglutide) is approved for T2D; no oral tirzepatide is currently available
- ✓You want the option with the longest real-world safety track record — semaglutide has been prescribed since 2017 vs tirzepatide since 2022
- ✓Your insurance covers semaglutide but not tirzepatide — formulary access varies by plan and can be the deciding factor
- ✓You are a first-line GLP-1 patient with T2D — extensive prescribing experience and robust evidence base make semaglutide a well-established starting option
Verdict
Studies show tirzepatide delivers approximately 7–9 percentage points more body weight loss than semaglutide and tends to produce fewer GI side effects at doses producing equivalent efficacy. For patients whose primary goal is maximum weight reduction, the clinical trial evidence consistently favors tirzepatide. However, semaglutide has a significantly longer safety record, uniquely demonstrated 20% cardiovascular event reduction in the SELECT trial, and offers an oral pill formulation — advantages that matter for patients with established cardiovascular disease or injection aversion. Neither medication is universally superior; the right choice depends on individual goals, health history, and access. Consult your healthcare provider to evaluate which option fits your clinical profile.
Start Your GLP-1 Journey
Both tirzepatide and semaglutide require a prescription. Telehealth platforms can connect you with a licensed provider who can evaluate your eligibility, order lab work, and manage your prescription — often entirely online. The following platforms offer GLP-1 programs.
Online evaluation, prescription management, and compounded GLP-1 options. Ships to most states.
Learn more →
Comprehensive weight management program combining GLP-1 medications with behavior change coaching.
Learn more →
Data-driven approach to weight loss; matches you to the most appropriate medication including GLP-1s.
Learn more →
Year-long metabolic reset program with GLP-1 prescriptions, lab testing, and one-on-one coaching.
Learn more →
Affordable access to GLP-1 prescriptions with straightforward pricing and provider consultations.
Learn more →
We may earn a commission when you visit a provider through our links. This doesn't affect our editorial independence. See our affiliate disclosure. Always research providers independently and consult your primary care physician before starting any new prescription medication.
References
- Once-weekly semaglutide in adults with overweight or obesity (STEP 1) (2021) — PubMed PMID 33567185
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) (2022) — PubMed PMID 35658024
- Tirzepatide once weekly for the treatment of obesity in adults with type 2 diabetes (SURMOUNT-2) (2023) — PubMed PMID 37421706
- Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) (2021) — PubMed PMID 34170647
- Tirzepatide for type 2 diabetes mellitus — SURPASS-4 trial (2021) — PubMed PMID 34293315
- Semaglutide and cardiovascular outcomes in patients with overweight or obesity (SELECT) (2023) — PubMed PMID 37952131
- Two-year effects of semaglutide in adults with overweight or obesity (STEP 5) (2022) — PubMed PMID 33861701
- Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension) (2022) — PubMed PMID 35441470
- Tirzepatide versus insulin degludec in insulin-naive patients with type 2 diabetes (SURPASS-3) (2021) — PubMed PMID 34170648
- GIP and GLP-1 as incretin hormones: lessons from single and dual incretin receptor knockouts in mice (2023) — PubMed PMID 37343348
- Semaglutide once weekly in patients with type 2 diabetes and obesity: SUSTAIN 8 (2018) — PubMed PMID 29727563
- Effects of liraglutide on heart failure after myocardial infarction in type 2 diabetes (2016) — PubMed PMID 26624366